Platelet inhibition by aspirin is diminished in patients during carotid surgery: A form of transient aspirin resistance?

Thrombosis and Haemostasis

Volumn 92, Issue 1, 2004, Pages 89-96

  Payne, David A ^a   Jones, Chris I ^a   Hayes, Paul D ^a   Webster, Sally E ^a   Naylor, A Ross ^a   Goodall, Alison H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Aspirin; Aspirin resistance; Carotid artery; Platelets; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; APYRASE; ARACHIDONIC ACID; COLLAGEN; HEPARIN; HIRUDIN; THROMBIN; YOHIMBINE;

ADULT; AGED; ANGIOPLASTY; ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR SURGERY; CAROTID ARTERY SURGERY; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENERAL ANESTHESIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN SECRETION; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOEMBOLISM; VASCULAR SURGERY;

EID: 3543005314     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-12-0758     Document Type: Article

References (39)

1. Antithombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002; 321: 71-86.
2. Roth GJ, Stanford N, Marjerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-6.
3. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. Br Med J 1994; 308: 159-68.
4. Barnett HJM, Taylor DW, Eliasziw M, et al, for the North American Symptomatic carotid endarterectomy Trial. The benefit of carotid endarterectomy in symptomatic patients with moderate and severe stenosis. N Engl J Med 1988; 339: 1415-25.
5. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179-84.
6. Boysen G, Sorensen PS, Juhler M. Danish very low-dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211-5.
7. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337: 1235-43.
8. Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40.
9. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function: Implications for clinical trials and therapy. Arch Pathol Lab Med 1994; 118: 801-4.
10. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
11. Gum PA, Kotte-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
12. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischaemic stroke. Stroke 1994; 25: 2231-6.
13. Buchanan RB, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-7.
14. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
15. Payne DA, Jones CI, Hayes PD, et al. Beneficial effects of Clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004; 109: 1476-81.
16. Patrignani P. Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
17. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 678-88
18. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs; the relationships among dose, effectiveness and side effects. Chest 2001; 119: 39S-63S.
19. Robless PA, Tegos TJ, Okonko D, et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 2002; 13: 231-9.
20. Wells J, Nicosia S, Wale C, et al. Thrombin generation in patients undergoing carotid endarterectomy: implications in acute vessel wall closure and antithrombotic therapy. Thromb Res 1994; 75: 419-26.
21. Kabakibi A. Vamvakas EC. Cannistraro PA, et al. Collagen-induced whole blood platelet aggregation in patients undergoing surgical procedures associated with minimal to moderate blood loss. Am J Clin Pathol 1998; 109: 392-8.
22. Lanza F, Bertetz A, Stierle A, et al. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-H1288.
23. Hjemdahl P, Chronos NAF, Wilson DJ, et al. Epinephrine sensitises human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994; 14: 77-84.
24. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced platelet activation in-vivo is only partly counteracted by aspirin. Circulation 1994; 89: 1951-7.
25. Chong BH, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol 1989; 43: 245-51.
26. Knight CJ, Panesara M, Wilson DJ, et al. Increased platelet responsiveness following coronary stenting: Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 1998; 19: 1239-48.
27. Horne MK, Chao ES. Heparin binding to resting and activated platelets. Blood 1989; 74: 238-43.
28. Olivecrona T, Bengtsson-Olivecrona G, Ostergaard P, et al. New aspects on heparin and lipoprotein metabolism. Haemostasis 1993; 23: 150-60.
29. Melin T, Qi C, Bengstsson-Olivecrona G, et al. Hydrolysis of chylomicron polyenoic fatty acid esters with lipoprotein lipase and hepatic lipase. Biochim Biophys Acta 1991; 1075: 259-66.
30. Sutherland M, Shankaranaraynan P, Schewe T, et al. Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of 12-lipoxygenase pathway of arachidonic acid metabolism. Biochem J 2001; 353: 91-100.
31. Buchanan MR, Butt RW, Hirsh J, et al. Role of lipoxygenase metabolism in platelet function: effect of aspirin and salicylate. Prostagland Leukot Med 1986; 21: 157-68.
32. Morita I, Murota SI. Role of 12-lipoxygenase products of arachidonic acid on platelet aggregation. Adv Prostaglandin Thromboxane Leukot Res 1987; 17: 219-23.
33. Calzade C, Vericel E, Lagarde M. Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation. Biochem J 1997; 325: 495-500.
34. Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12 lipoxygenase. Proc Natl Acad Sci USA 1998; 95: 3100-5.
35. Csiszar A, Stef G, Pacher P, et al. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 557-8.
36. Karim S, Habib A, Levy-Toledano S, et al. Cyclo-oxygenase -1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042-8.
37. Weber AA, Zimmermann N, Meyer-Kirchrath J, et al. Cyclo-oxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
38. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclo-oxygenase-2 expression is induced during human megakaryopoiesis and characterises newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
39. Reiter R, Resc U, Sinzinger H. Do human platelets express COX-2? Prostaglandins Leukot Essent Fatty Acids 2001; 64: 299-305.